OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

Opko Health Inc/  US68375N1037  /

NASDAQ
2024-05-10  10:00:00 PM Chg. +0.0200 Volume Bid11:14:01 PM Ask11:14:01 PM High Low
1.2800USD +1.59% 2.1 mill.
Turnover: 2.58 mill.		 1.2500Bid Size: 100 1.2900Ask Size: 6,500 1.2900 1.2400
GlobeNewswire 05-10 Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
GlobeNewswire 05-07 OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results
GlobeNewswire 05-03 OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024
GlobeNewswire 04-08 Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the...
GlobeNewswire 03-26 Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FD...
GlobeNewswire 03-20 Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire 03-08 Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
GlobeNewswire 03-05 AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the ...
GlobeNewswire 03-04 Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire 02-28 AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors
GlobeNewswire 02-27 OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
GlobeNewswire 02-22 OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
GlobeNewswire 02-02 SAB Biotherapeutics Announces Executive Leadership Change
GlobeNewswire 01-30 Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GlobeNewswire 01-09 OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 ...
GlobeNewswire 01-08 OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 01-05 OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029
GlobeNewswire 01-03 OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029
GlobeNewswire 01-03 Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
GlobeNewswire 2023-12-26 Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
GlobeNewswire 2023-11-29 Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatme...
GlobeNewswire 2023-11-14 Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision a...
GlobeNewswire 2023-11-09 Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-...
GlobeNewswire 2023-11-06 OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results
GlobeNewswire 2023-11-02 New Clinical Data on OPKO Health’s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023